Hayah Kassis-George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hayah Kassis-George has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Amresh Raina
Section of Advanced Heart Failure and Pulmonary Hypertension Cardiovascular Institute, Allegheny Health Network, Allegheny General Hospital Pittsburgh Pennsylvania USA
2 shared publications- Jyoti Mbbs Jain
Department of Internal Medicine, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA 15212, USA
2 shared publications - Pushan Aggarwal
Department of Internal Medicine, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA 15212, USA
2 shared publications - Rahul Karna
Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota Medical Center, Minneapolis, MN 55455, USA
2 shared publications Adeel Nasrullah
Allegheny Health Network - Allegheny General Hospital
1 shared publication- Adeel Nasrullah
Department of Pulmonary and Critical Care, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA 15212, USA
1 shared publication
Latest Publications
- Open Access
- 14 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8934
Obesity and Pulmonary Hypertension: A Contemporary Review
Obesity and pulmonary hypertension (PH) frequently coexist, but obesity is not a distinct PH group. This narrative review of the literature published through 27 September 2026 appraises the evidence by PH group. Obesity is most clearly linked to PH through intermediate conditions, particularly heart failure with preserved ejection fraction, obstructive sleep apnea, and obesity hypoventilation syndrome, and it can complicate hemodynamic classification because elevated intrathoracic pressure may raise the measured pulmonary arterial wedge pressure. Experimental studies suggest direct pulmonary vascular effects through adipokine imbalance, inflammation, altered estrogen metabolism, oxidative stress, and insulin resistance; however, an independent causal role of obesity in human pulmonary arterial hypertension has not been established. Small, mostly observational studies report lower estimated pulmonary pressures after bariatric surgery, but a benefit of intentional weight loss on invasive hemodynamics or clinical PH outcomes is unproven. Incretin-based therapies produce substantial weight loss and improve symptoms in obesity-related heart failure with preserved ejection fraction; acute human hemodynamic data are emerging, but long-term efficacy in PH has not been tested. Higher body mass index has been associated with lower observed mortality in several PH cohorts, possibly reflecting confounding and reverse causation. We distinguish established findings from hypotheses and highlight research priorities.
- 14 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8934
Open AccessObesity and Pulmonary Hypertension: A Contemporary Review
Obesity and pulmonary hypertension (PH) frequently coexist, but obesity is not a distinct PH group. This narrative review of the literature published through 27 September 2026 appraises the evidence by PH group. Obesity is most clearly linked to PH through intermediate conditions, particularly heart failure with preserved ejection fraction, obstructive sleep apnea, and obesity hypoventilation syndrome, and it can complicate hemodynamic classification because elevated intrathoracic pressure may raise the measured pulmonary arterial wedge pressure. Experimental studies suggest direct pulmonary vascular effects through adipokine imbalance, inflammation, altered estrogen metabolism, oxidative stress, and insulin resistance; however, an independent causal role of obesity in human pulmonary arterial hypertension has not been established. Small, mostly observational studies report lower estimated pulmonary pressures after bariatric surgery, but a benefit of intentional weight loss on invasive hemodynamics or clinical PH outcomes is unproven. Incretin-based therapies produce substantial weight loss and improve symptoms in obesity-related heart failure with preserved ejection fraction; acute human hemodynamic data are emerging, but long-term efficacy in PH has not been tested. Higher body mass index has been associated with lower observed mortality in several PH cohorts, possibly reflecting confounding and reverse causation. We distinguish established findings from hypotheses and highlight research priorities.
- Open Access
- 26 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6576
Cardiac Rehabilitation in Heart Failure: Evidence, Coverage, and Implementation
Cardiac rehabilitation (CR) is a multicomponent secondary prevention intervention that improves functional capacity and quality of life across cardiac diagnoses, yet remains markedly underused in heart failure (HF). Existing reviews treat efficacy, coverage, delivery, and equity separately; this narrative review integrates them to clarify why uptake in HF remains low despite an established evidence base. We searched PubMed/MEDLINE and the Cochrane Library from January 2009 through December 2025, prioritizing clinical practice guidelines, landmark trials, systematic reviews, registry analyses, and U.S. policy documents, with narrative synthesis across efficacy, coverage, delivery, and equity. In heart failure with reduced ejection fraction (HFrEF), exercise-based CR consistently improves peak oxygen consumption by roughly 15 to 17 percent, improves health status, and reduces short-term all-cause hospitalization. In heart failure with preserved ejection fraction (HFpEF), supervised exercise improves functional capacity and quality of life, but a large pragmatic outcome trial and Medicare coverage remain lacking. In appropriately selected, clinically stable patients, hybrid and virtual delivery produce comparable short-term functional and quality-of-life gains, with more limited direct evidence for hard clinical endpoints. Closing the HFpEF coverage gap, automating HFrEF referral, diversifying delivery, and embedding equity across the CR pipeline are actionable priorities for realizing CR’s potential in HF.
- 26 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6576
Open AccessCardiac Rehabilitation in Heart Failure: Evidence, Coverage, and Implementation
Cardiac rehabilitation (CR) is a multicomponent secondary prevention intervention that improves functional capacity and quality of life across cardiac diagnoses, yet remains markedly underused in heart failure (HF). Existing reviews treat efficacy, coverage, delivery, and equity separately; this narrative review integrates them to clarify why uptake in HF remains low despite an established evidence base. We searched PubMed/MEDLINE and the Cochrane Library from January 2009 through December 2025, prioritizing clinical practice guidelines, landmark trials, systematic reviews, registry analyses, and U.S. policy documents, with narrative synthesis across efficacy, coverage, delivery, and equity. In heart failure with reduced ejection fraction (HFrEF), exercise-based CR consistently improves peak oxygen consumption by roughly 15 to 17 percent, improves health status, and reduces short-term all-cause hospitalization. In heart failure with preserved ejection fraction (HFpEF), supervised exercise improves functional capacity and quality of life, but a large pragmatic outcome trial and Medicare coverage remain lacking. In appropriately selected, clinically stable patients, hybrid and virtual delivery produce comparable short-term functional and quality-of-life gains, with more limited direct evidence for hard clinical endpoints. Closing the HFpEF coverage gap, automating HFrEF referral, diversifying delivery, and embedding equity across the CR pipeline are actionable priorities for realizing CR’s potential in HF.
- Open Access
- 1 January 2025
- Published by XMLink in International Journal of Heart Failure
- Vol. 7 (1) , 1-5
Extreme Right Ventricular Pseudohypertrophy Due to Myocardial Edema
Alnaimat S, et al. Int J Heart Fail. 2025 Jan;7(1):1-5. https://doi.org/10.36628/ijhf.2024.0053
- 1 January 2025
- Published by XMLink in International Journal of Heart Failure
- Vol. 7 (1) , 1-5
Open AccessExtreme Right Ventricular Pseudohypertrophy Due to Myocardial Edema
Alnaimat S, et al. Int J Heart Fail. 2025 Jan;7(1):1-5. https://doi.org/10.36628/ijhf.2024.0053
- Open Access
- 17 February 2023
- Published by Springer Nature in Pulmonary Therapy
- Vol. 9 (2) , 207-221
Surgical and Device Interventions in the Treatment of Chronic Thromboembolic Disease
Chronic thromboembolic pulmonary disease (CTEPD) is characterized by unresolved clot burden in large pulmonary arteries, obstructive disease in smaller arteries, and increased downstream clot burden. This occurs in the setting of abnormal fibrinolysis or hematological disorders. Up to 50% of patients in some studies are unaware of a self-history of a deep venous thrombosis or pulmonary embolism. Ultimately, they present with symptoms of pulmonary hypertension (PH), which can result in right heart failure (RHF). Pulmonary endarterectomy (PEA) is curative, though many patients have prohibitive surgical risk or surgically inaccessible disease, warranting other interventions such as balloon pulmonary angioplasty (BPA) and medical therapy. Rarely, other treatment options may be implemented. We focus this review on PEA and BPA, with an overview of the history of CTEPD and the evolution of these procedures. We will briefly discuss other treatment modalities.
- 17 February 2023
- Published by Springer Nature in Pulmonary Therapy
- Vol. 9 (2) , 207-221
Open AccessSurgical and Device Interventions in the Treatment of Chronic Thromboembolic Disease
Chronic thromboembolic pulmonary disease (CTEPD) is characterized by unresolved clot burden in large pulmonary arteries, obstructive disease in smaller arteries, and increased downstream clot burden. This occurs in the setting of abnormal fibrinolysis or hematological disorders. Up to 50% of patients in some studies are unaware of a self-history of a deep venous thrombosis or pulmonary embolism. Ultimately, they present with symptoms of pulmonary hypertension (PH), which can result in right heart failure (RHF). Pulmonary endarterectomy (PEA) is curative, though many patients have prohibitive surgical risk or surgically inaccessible disease, warranting other interventions such as balloon pulmonary angioplasty (BPA) and medical therapy. Rarely, other treatment options may be implemented. We focus this review on PEA and BPA, with an overview of the history of CTEPD and the evolution of these procedures. We will briefly discuss other treatment modalities.
- Open Access
- 5 December 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (12) , e6631
Rapidly progressive pulmonary hypertension and right ventricular failure in a heart and kidney transplant recipient
A 54‐year‐old man status post heart and kidney transplant presented with dyspnea. Imaging was consistent with lymphangitic carcinomatosis (LC), in the setting of biopsy proven adenocarcinoma. He developed pulmonary hypertension (PH) and died of right ventricular failure (RVF) 3 weeks later. Acute PH with radiographic features of LC in a high‐risk patient warrants expedited malignancy investigation.
- 5 December 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (12) , e6631
Open AccessRapidly progressive pulmonary hypertension and right ventricular failure in a heart and kidney transplant recipient
A 54‐year‐old man status post heart and kidney transplant presented with dyspnea. Imaging was consistent with lymphangitic carcinomatosis (LC), in the setting of biopsy proven adenocarcinoma. He developed pulmonary hypertension (PH) and died of right ventricular failure (RVF) 3 weeks later. Acute PH with radiographic features of LC in a high‐risk patient warrants expedited malignancy investigation.
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Obesity and its Influence on the Development of Pulmonary Hypertension
There is a well-established association between obesity and various forms of pulmonary hypertension (PH). In recent years, our understanding of the role of obesity in the development of PH has changed significantly. In addition to its indirect contribution via effects on the cardiopulmonary system, obesity is now implicated in the development of pulmonary arterial hypertension (PAH) via insulin resistance, systemic inflammation and endothelial dysfunction. Weight loss improves pulmonary artery pressures, implicating weight loss as a potential strategy to improve PH. There is preliminary evidence of improvement in PH with bariatric surgery in obese patients. Here, we describe the role of obesity in PH, and discuss weight loss, and bariatric surgery, as a potential management strategy for PH.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessObesity and its Influence on the Development of Pulmonary Hypertension
There is a well-established association between obesity and various forms of pulmonary hypertension (PH). In recent years, our understanding of the role of obesity in the development of PH has changed significantly. In addition to its indirect contribution via effects on the cardiopulmonary system, obesity is now implicated in the development of pulmonary arterial hypertension (PAH) via insulin resistance, systemic inflammation and endothelial dysfunction. Weight loss improves pulmonary artery pressures, implicating weight loss as a potential strategy to improve PH. There is preliminary evidence of improvement in PH with bariatric surgery in obese patients. Here, we describe the role of obesity in PH, and discuss weight loss, and bariatric surgery, as a potential management strategy for PH.